Status:
COMPLETED
Atorvastatin in Moderate Active Crohns Disease
Lead Sponsor:
Skane University Hospital
Conditions:
Crohns Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Open pilot study to collect information regarding the effect of atorvastatin on patients with active Crohns disease.
Eligibility Criteria
Inclusion
- Clinical diagnosis of Crohns disease
- C-reactive protein level \> 2 mg/L in absence of an infection
- Fecal calprotectin \> 250 mg/kg or CDAI \> 150
Exclusion
- CDAI \> 450
- Prednisolone dosage above 15 mg/day
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00454545
Start Date
October 1 2006
End Date
October 1 2007
Last Update
October 22 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Division of Gastroenterology and Hepatology
Malmo, Sweden, 20502 Malmö